PHK
ANIP icon

Point72 Hong Kong’s ANI Pharmaceuticals ANIP Stock Holding History

Point72 Hong Kong’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-402
Closed -$13K – 146
2022
Q3 		$13K Buy
+402
New +$13.8K ﹤0.01% 1683

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Point72 Hong Kong's ANIP Position: Q4 2022 in Review

Point72 Hong Kong sold out of ANI Pharmaceuticals (ANIP) in Q4 2022, closing a stake of 402 shares — an estimated $13K sold.

Point72 Hong Kong first reported a position in ANIP in Q3 2022 and held it in 1 quarter. The position peaked at $13K in Q3 2022. 125 funds tracked by Wall St. Rank hold ANIP as of Q4 2022.

  • Point72 Hong Kong reported no remaining ANI Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 402 ANI Pharmaceuticals shares in Q4 2022, an estimated $13K.
  • Point72 Hong Kong first reported a position in ANI Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Point72 Hong Kong's ANI Pharmaceuticals position peaked at $13K in Q3 2022.
  • 125 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.